[go: up one dir, main page]

CL2010000694A1 - Compuestos derivados de acido 2-mertcaptociclopentano carboxilico inhibidores de tafla; su procedimiento de preparacion; composiciones farmaceuticas que los contienen; y el uso de ellos en la prevencion y tratamiento de complicaciones cardiovasculares, pulmonares y cerebrovasculares, solos o en asociacion. - Google Patents

Compuestos derivados de acido 2-mertcaptociclopentano carboxilico inhibidores de tafla; su procedimiento de preparacion; composiciones farmaceuticas que los contienen; y el uso de ellos en la prevencion y tratamiento de complicaciones cardiovasculares, pulmonares y cerebrovasculares, solos o en asociacion.

Info

Publication number
CL2010000694A1
CL2010000694A1 CL2010000694A CL2010000694A CL2010000694A1 CL 2010000694 A1 CL2010000694 A1 CL 2010000694A1 CL 2010000694 A CL2010000694 A CL 2010000694A CL 2010000694 A CL2010000694 A CL 2010000694A CL 2010000694 A1 CL2010000694 A1 CL 2010000694A1
Authority
CL
Chile
Prior art keywords
prevention
treatment
mertcaptocyclopentane
tafla
pulmonary
Prior art date
Application number
CL2010000694A
Other languages
English (en)
Inventor
Verbeuren Tony
Rupin Alain
De Nanteuil Guillaume
Gloanec Philippe
Parmentier Jean-Gilles
Guillouzic Anne-Francoise
Original Assignee
Servier Lab
Institut Nat Des Sciences Appliquees De Rouen
Centre Nat Rech Scient
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab, Institut Nat Des Sciences Appliquees De Rouen, Centre Nat Rech Scient filed Critical Servier Lab
Publication of CL2010000694A1 publication Critical patent/CL2010000694A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/61—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C327/00—Thiocarboxylic acids
    • C07C327/20—Esters of monothiocarboxylic acids
    • C07C327/32—Esters of monothiocarboxylic acids having sulfur atoms of esterified thiocarboxyl groups bound to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C07C327/34—Esters of monothiocarboxylic acids having sulfur atoms of esterified thiocarboxyl groups bound to carbon atoms of hydrocarbon radicals substituted by carboxyl groups with amino groups bound to the same hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/55—Acids; Esters

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)

Abstract

Compuestos derivados de ácido ciclobutano, ciclopentano o ciclohexano carboxílico; procedimiento de preparación de estos compuestos; composición farmacéutica que los contiene; y su uso para la prevención o el tratamiento del infarto al miocardio, angina de pecho y arteritis de los miembros inferiores, entre otras enfermedades.
CL2010000694A 2009-06-26 2010-06-25 Compuestos derivados de acido 2-mertcaptociclopentano carboxilico inhibidores de tafla; su procedimiento de preparacion; composiciones farmaceuticas que los contienen; y el uso de ellos en la prevencion y tratamiento de complicaciones cardiovasculares, pulmonares y cerebrovasculares, solos o en asociacion. CL2010000694A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0903111A FR2947266B1 (fr) 2009-06-26 2009-06-26 Nouveaux derives d'acide 2-mercaptocyclopentanecarboxylique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Publications (1)

Publication Number Publication Date
CL2010000694A1 true CL2010000694A1 (es) 2011-05-06

Family

ID=41594318

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2010000694A CL2010000694A1 (es) 2009-06-26 2010-06-25 Compuestos derivados de acido 2-mertcaptociclopentano carboxilico inhibidores de tafla; su procedimiento de preparacion; composiciones farmaceuticas que los contienen; y el uso de ellos en la prevencion y tratamiento de complicaciones cardiovasculares, pulmonares y cerebrovasculares, solos o en asociacion.

Country Status (28)

Country Link
US (1) US8309341B2 (es)
EP (1) EP2272826A1 (es)
JP (1) JP5238757B2 (es)
KR (1) KR101187394B1 (es)
CN (1) CN101928241A (es)
AP (1) AP2010005304A0 (es)
AR (1) AR078415A1 (es)
AU (1) AU2010202563A1 (es)
BR (1) BRPI1001935A2 (es)
CA (1) CA2707647A1 (es)
CL (1) CL2010000694A1 (es)
CO (1) CO6300113A1 (es)
CR (1) CR11494A (es)
CU (1) CU20100133A7 (es)
EA (1) EA017867B1 (es)
EC (1) ECSP10010292A (es)
FR (1) FR2947266B1 (es)
GT (1) GT201000184A (es)
IL (1) IL206405A0 (es)
MA (1) MA32340B1 (es)
MX (1) MX2010007070A (es)
NI (1) NI201000111A (es)
NZ (1) NZ586444A (es)
PE (1) PE20110022A1 (es)
TW (1) TWI380813B (es)
UY (1) UY32702A (es)
WO (1) WO2010149888A1 (es)
ZA (1) ZA201004398B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3046793B1 (fr) * 2016-01-14 2018-01-05 Les Laboratoires Servier Nouveaux derives de phosphinanes et azaphosphinanes, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CN109467506B (zh) * 2017-09-07 2021-12-07 江苏瑞科医药科技有限公司 一种取代苯乙酸衍生物的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4315031A (en) * 1977-09-01 1982-02-09 Science Union Et Cie Thiosubstituted amino acids
US4385062A (en) * 1980-01-09 1983-05-24 Gruppo Lepetit S.P.A. 1-[(-2-Mercaptocycloalkyl)carbonyl]-L-proline derivatives, the process for their manufacture, the intermediates for their synthesis and their use as anti-hypertensive agents
JPS5750955A (en) * 1980-09-12 1982-03-25 Hokko Chem Ind Co Ltd Oxime carbamate derivative and insecticide
JPH0565258A (ja) * 1991-07-03 1993-03-19 Nippon Bayeragrochem Kk 酢酸アニリド誘導体および除草剤
AU669372B2 (en) * 1992-05-29 1996-06-06 Procter & Gamble Pharmaceuticals, Inc. Sulfur-containing phosponate compounds for treating abnormal calcium and phosphate metabolism
CA2419633C (en) * 2000-08-17 2011-05-10 Pfizer Inc. Substituted imidazoles as tafia inhibitors
JP4472997B2 (ja) * 2002-03-21 2010-06-02 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト 血漿カルボキシペプチダーゼｂインヒビター
WO2004031216A1 (de) * 2002-10-04 2004-04-15 Pentapharm Ag Substrate für tafi (a)
DE102004020186A1 (de) * 2004-04-22 2005-11-17 Aventis Pharma Deutschland Gmbh Heterocyclylessigsäuren als Inhibitoren von TAFla

Also Published As

Publication number Publication date
JP5238757B2 (ja) 2013-07-17
FR2947266B1 (fr) 2011-06-17
KR20110000516A (ko) 2011-01-03
MA32340B1 (fr) 2011-06-01
BRPI1001935A2 (pt) 2012-03-06
AU2010202563A1 (en) 2011-01-20
AP2010005304A0 (en) 2010-06-30
CN101928241A (zh) 2010-12-29
JP2011006416A (ja) 2011-01-13
EA017867B1 (ru) 2013-03-29
ZA201004398B (en) 2011-03-30
US8309341B2 (en) 2012-11-13
TW201105322A (en) 2011-02-16
TWI380813B (zh) 2013-01-01
KR101187394B1 (ko) 2012-10-02
IL206405A0 (en) 2010-12-30
NI201000111A (es) 2010-12-17
WO2010149888A1 (fr) 2010-12-29
GT201000184A (es) 2012-04-30
EA201000867A1 (ru) 2010-12-30
US20100330064A1 (en) 2010-12-30
MX2010007070A (es) 2011-01-05
CR11494A (es) 2010-09-13
CA2707647A1 (fr) 2010-12-26
PE20110022A1 (es) 2011-02-04
AR078415A1 (es) 2011-11-09
CU20100133A7 (es) 2012-02-15
ECSP10010292A (es) 2011-06-30
NZ586444A (en) 2011-09-30
EP2272826A1 (fr) 2011-01-12
FR2947266A1 (fr) 2010-12-31
UY32702A (es) 2010-12-31
CO6300113A1 (es) 2011-07-21

Similar Documents

Publication Publication Date Title
CL2012003226A1 (es) Compuestos derivados de 5-fluoro-1h-pirazolopiridina ; procedimiento de preparacion de estos; composicion framaceutica que los comprende; y su uso en el tratamiento de enfermedades cardiovasculares, sexuales y metabolicas.
ECSP11011044A (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevención de diabetes
CL2013001600A1 (es) Compuestos derivados de acidos 1-bencilcicloalquilcarboxilicos sustituidos; procedimiento de preparacion de dichos compuestos; medicamento que los contiene; y su uso para el tratamiento y/o la prevencion de insuficiencia cardiaca, angina pectoris, hipertonia, afecciones tromboembolicas, insuficiencia renal, entre otras.
ECSP11011390A (es) Compuestos espiro-amidas sustituidas
CL2009001066A1 (es) Compuestos derivados del acido ciclopentano carboxilico sustituido; inhibidores del receptor lpa edg2; composicion farmaceutica; procedimiento de preparacion; y uso en el tratamiento de enfermedades cardiovasculares, inflamatorias, metabolicas, renales, pulmonares, oncologicas, inmunologicas y alergias, entre otras.
GT201400111A (es) Triazolopiridinas sustituidas
CL2013003598A1 (es) Compuestos derivados de benzooxazepinona, moduladores de canales de sodio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades seleccionadas de arritmias, insuficiencia cardiaca, angina, infarto al miocardio, diabetes, entre otras
UY32728A (es) Composición farmacéutica y procedimiento de tratamiento para la anticoncepción de emergencia
CL2012003317A1 (es) Compuestos derivados de 5,7-dihidro-6h-pirrolo[2,3-d]pirimidin-6-ona, moduladores de la produccion de guanosin monofosfato ciclico (cmpc); su composicion farmaceutica; utiles en el tratamiento de enfermedades cardiovasculares, disfuncion endotelial y diastolica, aterosclerosis, hipertension, trombosis, angina de pecho, entre otras.
UY33735A (es) Compuestos antivirales
ECSP077316A (es) Compuestos imidazo-3-il-amina bicíclicos sustituidos
MY150596A (en) Hsp90 inhibitors
UY32456A (es) Composicion famaceutica, forma farmaceutica, procedimiento para su preparación, metodos de tratamiento
MX2011008864A (es) Tetrahidroazolopirazinas sulfoniladas y su uso como productos medicinales.
WO2011048553A3 (en) Pharmaceutical compositions of pde-5 inhibitors and dapoxetine
CL2015000120A1 (es) Compuestos derivados de acidos 5-aminotetrahidroquinolin-2-carboxilicos; procedimiento de preparacion de dichos compuestos; medicamento que los contiene; y su uso para el tratamiento y/o la prevencion de hipertension pulmonar, insuficiencia cardiaca, angina de pecho, hipertension, enfermedades tromboembolicas, enfermedades fibroticas, isquemias, entre otras.
WO2010055082A3 (en) New crystal form of sunitinib malate
ECSP12012270A (es) Compuestos de pirazol como inhibidores del receptor sigma
ECSP14004595A (es) 2-tiopirimidinonas
ECSP099620A (es) Derivados de ciclohexano espirociclico
CL2012002905A1 (es) Compuestos derivados de heteroaril-ciclohexil-tetraazabenzo(e)azulenos sustituidos, moduladores del receptor de vasopresina v1a; procedimiento de preparacion; composición farmacéutica; y su uso para la prevención o el tratamiento de la dismenorrea, disfunción sexual masculina o femenina, ansiedad, entre otros.
EA201200850A1 (ru) Фармацевтическая композиция, содержащая олигопептиды
CU24041B1 (es) Procedimiento de preparación del lipopolisacárido de ochrobactrum intermedium lmg3306 y la composición que lo contiene
CR20160433A (es) Nuevos compuestos
CL2013002129A1 (es) Compuestos derivados de acido 3-heteroaroilamino-propionico sustituidos, como inhibidores de la proteasa catepsina a; procedimiento de preparacion; composicion farmaceutica que los comprende; y su uso para el tratamiento de insuficiencia cardiaca, enfermedades inmunologicas, asma, dolor, entre otras.